KROS
Keros Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$372.90M
P/E Ratio
5.32
EPS
$2.30
Beta
0.99
52W High
$22.55
52W Low
$10.41
50-Day MA
$14.28
200-Day MA
$15.77
Dividend Yield
—
Profit Margin
35.60%
Forward P/E
15.65
PEG Ratio
—
About Keros Therapeutics Inc
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with a great unmet medical need. The company is headquartered in Lexington, Massachusetts.
Fundamentals
| Revenue (TTM) | $244.06M |
| Gross Profit (TTM) | $116.92M |
| EBITDA | $72.08M |
| Operating Margin | -7577.00% |
| Return on Equity | 19.90% |
| Return on Assets | 9.25% |
| Revenue/Share (TTM) | $6.56 |
| Book Value | $15.51 |
| Price-to-Book | 0.78 |
| Price-to-Sales (TTM) | 1.53 |
| EV/Revenue | 6490.26 |
| EV/EBITDA | -13.05 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -87.30% |
| Shares Outstanding | $19.72M |
| Float | $19.17M |
| % Insiders | 5.60% |
| % Institutions | 103.52% |
Analyst Ratings
Consensus ($22.57 target)
5
Buy4
HoldData last updated: 4/8/2026